Keymed has built a highly differentiated and diversified pipeline in autoimmune diseases, tumor and chronic diseases, which covers over 30 self-developed Class I novel drug development programs, including：

•13 antibodies in multiple clinical stages

•2 receiving funding support from National New Drug Innovation Major Project and the 13th Five-Year Plan

•The core product Stapokibart（Kangyueda®）(approved for 3 indications, Breakthrough Therapy Designation and Priority Review by CDE) 

•The world’s first Claudin 18.2 ADC drug (Orphan Drug and Fast Track Designation by FDA)